Sanofi (NASDAQ:SNY) Shares Gap Down – Time to Sell?

Sanofi (NASDAQ:SNY)’s share price gapped down before the market opened on Wednesday . The stock had previously closed at $48.94, but opened at $47.74. Sanofi shares last traded at $48.00, with a volume of 471,933 shares traded.

Analyst Ratings Changes

Several research firms have weighed in on SNY. Citigroup upgraded shares of Sanofi to a “strong-buy” rating in a report on Tuesday, September 17th. StockNews.com cut Sanofi from a “buy” rating to a “hold” rating in a report on Thursday, December 12th. Two equities research analysts have rated the stock with a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, Sanofi presently has an average rating of “Moderate Buy” and a consensus price target of $57.50.

Sanofi Trading Up 1.0 %

The company’s fifty day simple moving average is $50.41 and its 200-day simple moving average is $52.02. The company has a market capitalization of $120.55 billion, a P/E ratio of 24.23, a PEG ratio of 1.23 and a beta of 0.58. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.65 and a current ratio of 1.00.

Sanofi (NASDAQ:SNY) last issued its earnings results on Friday, October 25th. The company reported $1.57 EPS for the quarter, topping analysts’ consensus estimates of $0.22 by $1.35. The company had revenue of $13.44 billion for the quarter, compared to the consensus estimate of $16.59 billion. Sanofi had a net margin of 9.96% and a return on equity of 27.45%. Sanofi’s quarterly revenue was up 12.3% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.55 earnings per share. Research analysts predict that Sanofi will post 4.06 earnings per share for the current year.

Institutional Investors Weigh In On Sanofi

Large investors have recently bought and sold shares of the company. Barrow Hanley Mewhinney & Strauss LLC raised its stake in shares of Sanofi by 113.8% in the second quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 5,943,547 shares of the company’s stock worth $288,381,000 after purchasing an additional 3,164,092 shares during the last quarter. Magnetar Financial LLC increased its stake in Sanofi by 1,153.1% during the second quarter. Magnetar Financial LLC now owns 2,506,286 shares of the company’s stock worth $121,605,000 after acquiring an additional 2,306,286 shares during the last quarter. Jennison Associates LLC increased its stake in Sanofi by 938.0% during the third quarter. Jennison Associates LLC now owns 1,904,445 shares of the company’s stock worth $109,753,000 after purchasing an additional 1,720,972 shares during the period. Thrivent Financial for Lutherans lifted its stake in Sanofi by 28,890.2% during the third quarter. Thrivent Financial for Lutherans now owns 1,429,219 shares of the company’s stock worth $82,366,000 after purchasing an additional 1,424,289 shares during the last quarter. Finally, Bank of New York Mellon Corp grew its stake in shares of Sanofi by 19.0% in the 2nd quarter. Bank of New York Mellon Corp now owns 8,594,740 shares of the company’s stock valued at $417,017,000 after purchasing an additional 1,370,232 shares during the last quarter. Institutional investors own 14.04% of the company’s stock.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.